MEDP (Medpace Holdings) Cyclically Adjusted Revenue per Share: $46.83 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEDP Medpace Holdings Inc MEDP
97 GF Score
Price $573.29
GF Value $530.65
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Cyclically Adjusted Revenue per Share?

Medpace Holdings MEDP -0.57% 97 Cyclically Adjusted Revenue per Share is $46.83 as of Jun. 2026. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $530.65 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medpace Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was $24.772. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $46.83 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Medpace Holdings's average Cyclically Adjusted Revenue Growth Rate was 26.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-03), Medpace Holdings's current stock price is $573.29. Medpace Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $46.83. Medpace Holdings's Cyclically Adjusted PS Ratio of today is 12.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 15.39. The lowest was 8.20. And the median was 10.94.


Medpace Holdings  (NAS:MEDP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medpace Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=573.29/46.83
=12.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 15.39. The lowest was 8.20. And the median was 10.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medpace Holdings Cyclically Adjusted Revenue per Share Related Terms


Medpace Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Cyclically Adjusted Revenue per Share Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 33.07 41.35

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.09 39.32 41.35 44.22 46.83

MEDP vs GH, ICLR, RVTY: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PS Ratio falls into.


MEDP
97GF Score
Medpace Holdings Inc MEDP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medpace Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=24.772/333.9520*333.9520
=24.772

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.865 241.428 3.963
201612 2.564 241.432 3.547
201703 2.568 243.801 3.518
201706 2.602 244.955 3.547
201709 2.813 246.819 3.806
201712 2.985 246.524 4.044
201803 4.474 249.554 5.987
201806 4.641 251.989 6.151
201809 4.828 252.439 6.387
201812 5.156 251.233 6.854
201903 5.384 254.202 7.073
201906 5.726 256.143 7.465
201909 5.715 256.759 7.433
201912 6.084 256.974 7.906
202003 6.071 258.115 7.855
202006 5.492 257.797 7.114
202009 6.100 260.280 7.827
202012 6.890 260.474 8.834
202103 6.887 264.877 8.683
202106 7.379 271.696 9.070
202109 9.164 274.310 11.156
202112 6.363 278.802 7.622
202203 9.101 287.504 10.571
202206 10.423 296.311 11.747
202209 11.898 296.808 13.387
202212 12.167 296.797 13.690
202303 13.499 301.836 14.935
202306 14.596 305.109 15.976
202309 15.506 307.789 16.824
202312 15.650 306.746 17.038
202403 15.970 312.332 17.075
202406 16.459 314.175 17.495
202409 16.620 315.301 17.603
202412 16.834 315.605 17.813
202503 17.905 319.799 18.697
202506 20.702 322.561 21.433
202509 22.900 324.800 23.545
202512 24.448 324.054 25.195
202603 24.398 330.213 24.674
202606 24.772 333.952 24.772

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $46.83 mean?
Medpace Holdings (MEDP) has a Cyclically Adjusted Revenue per Share of $46.83 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Cyclically Adjusted Revenue per Share too high?
Medpace Holdings' current Cyclically Adjusted Revenue per Share is $46.83. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Cyclically Adjusted Revenue per Share compare to GH and ICLR?
Medpace Holdings' Cyclically Adjusted Revenue per Share of $46.83 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Cyclically Adjusted Revenue per Share is $46.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $530.65, compared to a current price of $573.29 — trading 8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $46.83. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current Cyclically Adjusted Revenue per Share is $46.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of $573.29 is trading 8% above its estimated GF Value™ of $530.65. GuruFocus considers Medpace Holdings to be Fairly Valued.

Key valuation signals for MEDP:

  • Cyclically Adjusted Revenue per Share: $46.83
  • GF Value™: $530.65 vs. price of $573.29 (8% above fair value)
  • GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Other Exchanges MEDP:Mexico01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score

Get the complete analysis for MEDP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$573.29
Price
$530.65
GF Value